In addition to the ten data abstracts,
"We are excited that ten separate abstracts with Nektar pipeline molecules have been accepted for presentation at this year's
Oral Presentation:
Abstract Title:"Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma"
Abstract: #O4
Presenter: Dr.
Session Title: Cytokines Reinvented
Date:
Poster Presentations:
Combination Therapy
Abstract #P364: "Systemic anti-tumor immunity and immune memory formation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214", Kivimae, S., et al.
Session Date and Time:
Abstract #P378:"NKTR-214 (CD122-biased agonist) and NKTR-262 (TLR7/8 agonist) combination treatment pairs local innate immune activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity", Rolig, A., et al.
Session Date and Time:
Abstract #P368:"Combination of a Dipeptidyl Peptidase Inhibitor BXCL701 and Biased CD122 Agonist NKTR-214 with Anti-PD1 Provides Functional Immunological Memory through Inflammatory Cell Death", MacDougall, J., et al.
Session Date and Time:
Abstract #P348:"Survival and immune modulation in homologous recombination deficient murine ovarian tumors using the PARP inhibitor, rucaparib and immune agonist, NKTR-214", Charych, D., et al.
Session Date and Time:
Cytokines in Anti-Tumor Immunity
Abstract #P418:"Pre-clinical investigation of NKTR-255, a polymer-conjugated IL-15 with a potent NK cell dependent anti-tumor efficacy", Miyazaki, T., et al.
Session Date and Time:
Abstract #P419:"NKTR-214 in combination with radiation produces a potent in situ vaccine in the syngeneic B78 melanoma model", Sondel, P., et al.
Session Date and Time:
Abstract #P422:"A polymer-associated human IL-15 (NKTR-255) has optimized biological activity and unique mechanisms of action on CD8 T Cells and NK Cells", Robinson T., et al.
Session Date and Time:
Abstract #P424:"NKTR-214, an engineered IL-2, selectively depletes intratumoral Tregs and expands immunotherapy-induced effector T cell responses", Sharma, M., et al.
Session Date and Time:
Mechanisms of Resistance to Immunotherapy
Abstract #P557:"Overcoming genetically-based resistance mechanisms to PD-1 blockade", Torrejon, D., et al.
Session Date and Time:
Company to Host Webcast Conference Call at
The company will host a webcast conference call with melanoma specialists and company management on
About Nektar
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements which can be identified by words such as: "will," "believe," "can," "serve" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the therapeutic potential of our pipeline molecules alone or in combination with other therapeutic agents, and the availability of results and outcomes from clinical and preclinical studies of our new drug candidates. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of our pipeline molecules are based on preclinical and clinical findings and observations; (ii) NKTR-214 and most of our pipeline molecules are in early stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage for one or more of the cancer indications being studied prior to regulatory approval due to lack of sufficient efficacy, safety considerations or other factors that impact drug development; (iii) data reported from ongoing preclinical and clinical trials are necessarily interim data only and the final results will change based on continuing observations; (iv) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of potential new drug candidates (such as NKTR-214, NKTR-262 and NKTR-255) is therefore very uncertain and unpredictable; (v) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vi) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q filed with the
Contact:
For Investors:
415-482-5585
415-482-5593
For Media:
973-271-6085
dan@1abmedia.com
View original content:http://www.prnewswire.com/news-releases/nektar-therapeutics-announces-ten-abstracts-accepted-for-presentation-at-the-2018-society-for-immunotherapy-of-cancer-sitc-annual-meeting-300722461.html
SOURCE